• 1. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 2. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 3. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 4. Aggregation-induced emission of luminol: a novel strategy for fluorescence ratiometric detection of ALP and As(v) with high sensitivity and selectivity?
  Yuan-Jun Tong,Lu-Dan Yu,Lu-Lu Wu,Shu-Ping Cao,Ru-Ping Liang,Li Zhang,Xing-Hua Xia,Jian-Ding Qiu Chem. Commun., 2018,54, 7487-7490
• 5. An easier analysis of complex mixtures with highly resolved and sensitivity enhanced 2D quantitative NMR: application to tracking sugar phosphates in plants?
  Soumaya Khlifi,Gregory Mouille,Jonathan Farjon Anal. Methods, 2017,9, 2328-2333

Recent Advances in the Study of 3-Chloro-2-(pyrrolidin-1-yl)aniline (CAS: 58785-05-0) in Chemical Biology and Pharmaceutical Research

The compound 3-Chloro-2-(pyrrolidin-1-yl)aniline (CAS: 58785-05-0) has recently gained significant attention in chemical biology and pharmaceutical research due to its unique structural features and potential therapeutic applications. This aromatic amine derivative, characterized by a chloro-substituted aniline core and a pyrrolidine moiety, has emerged as a promising scaffold for drug discovery. Recent studies have explored its role as a building block for the synthesis of biologically active molecules, particularly in the development of kinase inhibitors and GPCR modulators.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility as a key intermediate in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. Researchers successfully incorporated 3-Chloro-2-(pyrrolidin-1-yl)aniline into a series of pyrimidine derivatives, resulting in compounds with improved selectivity and pharmacokinetic profiles compared to existing BTK inhibitors. The study highlighted the importance of the pyrrolidine nitrogen in forming crucial hydrogen bonds with the kinase's hinge region, while the chloro group contributed to optimal positioning within the binding pocket.

In the field of central nervous system (CNS) drug development, recent investigations have focused on the compound's potential as a precursor for dopamine receptor ligands. A 2024 structure-activity relationship (SAR) study published in Bioorganic & Medicinal Chemistry Letters revealed that modifications of the 3-Chloro-2-(pyrrolidin-1-yl)aniline scaffold could yield selective D3 receptor partial agonists with potential applications in Parkinson's disease and substance use disorders. The research team noted that the compound's balanced lipophilicity and molecular weight made it particularly suitable for crossing the blood-brain barrier.

From a synthetic chemistry perspective, advances in the preparation of 3-Chloro-2-(pyrrolidin-1-yl)aniline have been reported in several recent publications. A 2023 Organic Process Research & Development paper described an optimized, scalable synthesis route that improved yield from 62% to 89% while reducing the number of purification steps. The new protocol employed a Buchwald-Hartwig amination as the key step, followed by a selective chlorination, addressing previous challenges with regioselectivity and byproduct formation.

Analytical characterization of 3-Chloro-2-(pyrrolidin-1-yl)aniline has also seen progress, with a 2024 Journal of Pharmaceutical and Biomedical Analysis publication presenting a validated HPLC method for its quantification in complex matrices. The method demonstrated excellent linearity (R2 > 0.999) across a concentration range of 0.1-100 μg/mL, with precision and accuracy meeting ICH guidelines. This development is particularly significant for quality control in pharmaceutical manufacturing processes utilizing this intermediate.

Looking forward, the unique properties of 3-Chloro-2-(pyrrolidin-1-yl)aniline continue to inspire innovative applications. Current research directions include its incorporation into PROTAC (proteolysis targeting chimera) molecules for targeted protein degradation and its use as a fluorescent probe for studying protein-ligand interactions. The compound's versatility and the growing body of research supporting its utility suggest it will remain an important tool in medicinal chemistry and drug discovery efforts for years to come.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)